Literature DB >> 15772896

Fingolimod. Mitsubishi Pharma/Novartis.

Francis J Dumont1.   

Abstract

Mitsubishi Pharma Corp and Novartis AG are developing fingolimod, an orally active immunosuppressant affecting lymphocyte re-circulation, for the potential prevention of transplant rejection and the treatment of autoimmune diseases, including multiple sclerosis. Fingolimodis a synthetic sphingosine analog that becomes phosphorylated in vivo and acts as a sphingosine-1-phosphate receptor agonist.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15772896

Source DB:  PubMed          Journal:  IDrugs        ISSN： 1369-7056


  4 in total

Review 1.  Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.

Authors:  Y Chen; C Peng; C Sullivan; D Li; S Li
Journal:  Leukemia       Date:  2010-06-24       Impact factor: 11.528

2.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

3.  Fingolimod and changes in hematocrit, hemoglobin and red blood cells of patients with multiple sclerosis.

Authors:  Ali Momeni; Rana Abrishamkar; Fatemeh Panahi; Sepehr Eslami; Nooshin Tavoosi; Aryan Rafiee Zadeh
Journal:  Am J Clin Exp Immunol       Date:  2019-08-15

4.  Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.

Authors:  Geoffrey Shouse; Rosalia de Necochea-Campion; Saied Mirshahidi; Xuan Liu; Chien-Shing Chen
Journal:  Oncotarget       Date:  2016-09-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.